Psychedelic Drug Gets Millions for Veteran PTSD

The U.S. Department of Health and Human Services has announced a significant commitment of up to $4.9 million over five years to advance research into the psychedelic drug ibogaine. This funding, channeled through ARPA-H, will focus on the regulatory and manufacturing aspects necessary for future studies. The initiative specifically aims to explore ibogaine's potential as a treatment for post-traumatic stress disorder (PTSD) and other severe mental illnesses, with a particular emphasis on veterans.

Ibogaine, derived from African plants, is known for its potent psychoactive effects and has demonstrated promise in treating addiction and symptoms of PTSD and brain injury. While it carries cardiac risks, the government is pursuing its potential as a novel therapeutic option. Early studies, including a 2024 Stanford University research, reported an 88% decrease in PTSD symptoms among special forces veterans after a single ibogaine treatment session, alongside reductions in depression and anxiety.

This investment is part of a broader federal effort to explore psychedelic therapies. The National Institute of Mental Health has also launched a $20 million funding opportunity for research networks studying other psychedelic treatments like ketamine and psilocybin. The outcomes of these research endeavors, including clinical trials and manufacturing developments, will be made public, with the goal of accelerating the availability of potential new mental health treatments.